ValiRx Regulatory News (VAL)

3 February 2025

ValiRx plc

("ValiRx" or the "Company")

Inaphaea Evaluation and Commercial Use Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with UK based Screenin3d Limited ("Screenin3D") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in Screenin3D's state-of-the-art UpScale3Dlab-on-a-chip technology with associated image analysis software. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer in-vitro 3D tumour model which will then be offered for commercial services by Screenin3D and Inaphaea. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Inaphaea will be entitled to an upfront fee of £10,000 per PDC cell line upon commercialisation of the models. Screenin3D have an option to buy the commercial rights in relation to the PDCs and support future drug development. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Mark Eccleston, CEO of ValiRx commented "We are continuously looking for commercial partners to accelerate Inaphaea's capabilities and market access. Screenin3D's UpScale3Dlab-on-a-chip platform and established customer base is a perfect example of technology and commercial synergy for Inaphaea's biobank of Patient Derived Cells. We look forward to the development of the triple negative breast cancer models which will also be used to support ValiRx's cytolytic peptide program through our partially owned subsidiary, Cytolytix. The data sets generated, alongside standard of care drugs, will be used to support commercialisation of the new UpScale3D PDC models and we look forward to publishing the results with ScreenIn3D in due course."

Michele Zagnoni, CEO of Screenin3d Limited, commented "We are excited to collaborate with Inaphaea to expand commercial opportunities for accelerating drug discovery and translational research. Combining our patented UpScale3D lab-on-a-chip technology with Inaphaea's biobank of Patient Derived Cells, this partnership will offer novel and powerful preclinical services in oncology and women's health, enabling us to facilitate large numbers of drug tests on very small quantities of predictive human samples of disease."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com